Equities Analysts Offer Predictions for KALV Q4 Earnings

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) – Investment analysts at Leerink Partnrs issued their Q4 2025 EPS estimates for KalVista Pharmaceuticals in a report issued on Tuesday, March 25th. Leerink Partnrs analyst J. Schwartz forecasts that the specialty pharmaceutical company will post earnings per share of ($0.77) for the quarter. The consensus estimate for KalVista Pharmaceuticals’ current full-year earnings is ($3.56) per share. Leerink Partnrs also issued estimates for KalVista Pharmaceuticals’ Q1 2026 earnings at ($0.72) EPS, Q2 2026 earnings at ($0.60) EPS, Q3 2026 earnings at ($0.53) EPS, Q4 2026 earnings at ($0.47) EPS, FY2026 earnings at ($2.41) EPS and FY2027 earnings at ($1.27) EPS.

Several other equities research analysts have also recently weighed in on KALV. Needham & Company LLC reiterated a “buy” rating and issued a $28.00 target price on shares of KalVista Pharmaceuticals in a report on Wednesday. Jones Trading reaffirmed a “buy” rating and issued a $30.00 price objective on shares of KalVista Pharmaceuticals in a research note on Wednesday. Cantor Fitzgerald reiterated an “overweight” rating on shares of KalVista Pharmaceuticals in a report on Monday, December 9th. Bank of America started coverage on shares of KalVista Pharmaceuticals in a report on Wednesday, December 18th. They issued a “buy” rating and a $22.00 price target for the company. Finally, Citizens Jmp upgraded shares of KalVista Pharmaceuticals to a “strong-buy” rating in a research note on Friday, January 31st. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $24.83.

KalVista Pharmaceuticals Stock Down 3.3 %

Shares of NASDAQ:KALV opened at $11.93 on Friday. The business’s 50 day moving average is $10.56 and its 200 day moving average is $10.25. The stock has a market cap of $593.11 million, a P/E ratio of -3.28 and a beta of 0.76. KalVista Pharmaceuticals has a 52-week low of $7.30 and a 52-week high of $15.50.

Insider Buying and Selling at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, major shareholder Venrock Healthcare Capital Par purchased 14,562 shares of KalVista Pharmaceuticals stock in a transaction dated Monday, February 3rd. The shares were acquired at an average cost of $9.22 per share, with a total value of $134,261.64. Following the completion of the transaction, the insider now owns 5,012,796 shares in the company, valued at approximately $46,217,979.12. This trade represents a 0.29 % increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Paul K. Audhya sold 3,125 shares of the firm’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $9.82, for a total value of $30,687.50. Following the completion of the sale, the insider now directly owns 100,334 shares of the company’s stock, valued at $985,279.88. The trade was a 3.02 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders bought 236,055 shares of company stock valued at $2,162,146 and sold 17,292 shares valued at $184,625. Insiders own 10.50% of the company’s stock.

Institutional Investors Weigh In On KalVista Pharmaceuticals

A number of large investors have recently modified their holdings of the business. Aquatic Capital Management LLC acquired a new stake in KalVista Pharmaceuticals in the 4th quarter worth approximately $44,000. Tower Research Capital LLC TRC raised its holdings in shares of KalVista Pharmaceuticals by 666.9% in the fourth quarter. Tower Research Capital LLC TRC now owns 6,327 shares of the specialty pharmaceutical company’s stock worth $54,000 after buying an additional 5,502 shares during the last quarter. Legal & General Group Plc lifted its stake in shares of KalVista Pharmaceuticals by 22.5% during the fourth quarter. Legal & General Group Plc now owns 8,144 shares of the specialty pharmaceutical company’s stock worth $69,000 after buying an additional 1,494 shares during the period. Martin Worley Group purchased a new stake in shares of KalVista Pharmaceuticals during the fourth quarter valued at $86,000. Finally, China Universal Asset Management Co. Ltd. grew its holdings in shares of KalVista Pharmaceuticals by 24.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,329 shares of the specialty pharmaceutical company’s stock valued at $87,000 after buying an additional 2,043 shares during the last quarter.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).